Pityriasis lichenoides chronica associated with use of HMG-CoA reductase inhibitors

West Indian Med J. 2012 Oct;61(7):743-5.


Herein, we present three cases of Pityriasis lichenoides chronica (PLC) in patients who developed the rash after use of 3-hydroxy-3-methyl-glutaryl-Coenzyme A (HMG-CoA) reductase inhibitors. The patients had complete resolution after standard treatment by dermatologists and withdrawal of the offending agents. In one case, the patient had a previous episode of a similar rash that occurred with HMG-CoA reductase inhibitors use many years previously. Pityriasis lichenoides chronica is a condition of unknown aetiology. Several agents have been associated with its presentation. We postulate HMG-CoA reductase inhibition in skin presents a final common pathway for the presentation of PLC in select patients.

Publication types

  • Case Reports

MeSH terms

  • Aged
  • Drug Eruptions / etiology
  • Female
  • Humans
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors / adverse effects*
  • Male
  • Middle Aged
  • Pityriasis Lichenoides / chemically induced*


  • Hydroxymethylglutaryl-CoA Reductase Inhibitors